

Tom T Shimabukuro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3045054/publications.pdf>

Version: 2024-02-01

40
papers

4,338
citations

172386

29
h-index

302012

39
g-index

44
all docs

44
docs citations

44
times ranked

4649
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices â€” United States, December 2021. Morbidity and Mortality Weekly Report, 2022, 71, 90-95.	9.0	82
2	Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccinationâ€”United States, December 2020 to August 2021. Annals of Internal Medicine, 2022, 175, 513-522.	2.0	93
3	Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. JAMA - Journal of the American Medical Association, 2022, 327, 331.	3.8	434
4	Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults â€” United States, September 22, 2021â€”February 6, 2022. Morbidity and Mortality Weekly Report, 2022, 71, 249-254.	9.0	59
5	Expected Rates of Select Adverse Events After Immunization for Coronavirus Disease 2019 Vaccine Safety Monitoring. Journal of Infectious Diseases, 2022, 225, 1569-1574.	1.9	10
6	Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe. Lancet Infectious Diseases, The, 2022, 22, 802-812.	4.6	102
7	Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12â€”17 Years â€” United States, December 9, 2021â€”February 20, 2022. Morbidity and Mortality Weekly Report, 2022, 71, 347-351.	9.0	33
8	Safety of COVID-19 Vaccination in United States Children Ages 5 to 11 Years. Pediatrics, 2022, 150, .	1.0	37
9	First Month of COVID-19 Vaccine Safety Monitoring â€” United States, December 14, 2020â€”January 13, 2021. Morbidity and Mortality Weekly Report, 2021, 70, 283-288.	9.0	314
10	Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine â€” United States, December 14â€”23, 2020. American Journal of Transplantation, 2021, 21, 1332-1337.	2.6	37
11	Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine. JAMA - Journal of the American Medical Association, 2021, 325, 780.	3.8	247
12	Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine â€” United States, December 21, 2020â€”January 10, 2021. American Journal of Transplantation, 2021, 21, 1326-1331.	2.6	39
13	Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the USâ€”December 14, 2020-January 18, 2021. JAMA - Journal of the American Medical Association, 2021, 325, 1101.	3.8	335
14	Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine â€” United States, Marchâ€”April 2021. Morbidity and Mortality Weekly Report, 2021, 70, 680-684.	9.0	152
15	Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination â€” Five U.S. Mass Vaccination Sites, April 2021. Morbidity and Mortality Weekly Report, 2021, 70, 685-688.	9.0	58
16	US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. JAMA - Journal of the American Medical Association, 2021, 325, 2448.	3.8	463
17	U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines. Vaccine, 2021, 39, 3666-3677.	1.7	61
18	Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices â€” United States, June 2021. Morbidity and Mortality Weekly Report, 2021, 70, 977-982.	9.0	431

#	ARTICLE	IF	CITATIONS
19	Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson) Tj ETQq1 Committee on Immunization Practices â€” United States, July 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1094-1099.	1 0.784314 rgBT /Cv	169
20	COVID-19 Vaccine Safety in Adolescents Aged 12â€”17 Years â€” United States, December 14, 2020â€”July 16, 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1053-1058.	9.0	123
21	COVID-19 Vaccine Safety in Children Aged 5â€”11 Years â€” United States, November 3â€”December 19, 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1755-1760.	9.0	126
22	Reports of atypical shoulder pain and dysfunction following inactivated influenza vaccine, Vaccine Adverse Event Reporting System (VAERS), 2010â€”2017. Vaccine, 2020, 38, 1137-1143.	1.7	41
23	Shoulder Injury Related to Vaccine Administration (SIRVA): Petitioner claims to the National Vaccine Injury Compensation Program, 2010â€”2016. Vaccine, 2020, 38, 1076-1083.	1.7	50
24	Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012â€”13, 2013â€”14, and 2014â€”15. Vaccine, 2019, 37, 6673-6681.	1.7	39
25	The MMR Vaccine and Autism. Annual Review of Virology, 2019, 6, 585-600.	3.0	67
26	Safety of the 9-Valent Human Papillomavirus Vaccine. Pediatrics, 2019, 144, .	1.0	39
27	Vaccine Safety. , 2019, , 1-24.		0
28	Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) â€” United States, October 2017â€”June 2018. Morbidity and Mortality Weekly Report, 2019, 68, 91-94.	9.0	37
29	Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009â€”2015. Vaccine, 2018, 36, 1781-1788.	1.7	51
30	Safety of vaccines that have been kept outside of recommended temperatures: Reports to the Vaccine Adverse Event Reporting System (VAERS), 2008â€”2012. Vaccine, 2018, 36, 553-558.	1.7	28
31	Post-licensure safety surveillance of zoster vaccine live (ZostavaxÂ®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006â€”2015. Human Vaccines and Immunotherapeutics, 2018, 14, 1963-1969.	1.4	24
32	Safety of bivalent human papillomavirus vaccine in the US vaccine adverse event reporting system (VAERS), 2009â€”2017. British Journal of Clinical Pharmacology, 2018, 84, 2928-2932.	1.1	18
33	<i>Notes from the Field:</i> Vaccine Administration Errors Involving Recombinant Zoster Vaccine â€” United States, 2017â€”2018. Morbidity and Mortality Weekly Report, 2018, 67, 585-586.	9.0	11
34	Cognitive testing to evaluate revisions to the Vaccine Adverse Event Reporting System (VAERS) reporting form. Vaccine, 2017, 35, 2295-2297.	1.7	2
35	Reports of Postural Orthostatic Tachycardia Syndrome After Human Papillomavirus Vaccination in the Vaccine Adverse Event Reporting System. Journal of Adolescent Health, 2017, 61, 577-582.	1.2	28
36	Unintentional administration of insulin instead of influenza vaccine: a case study and review of reports to US vaccine and drug safety monitoring systems. Drugs and Therapy Perspectives, 2016, 32, 439-446.	0.3	1

#	ARTICLE	IF	CITATIONS
37	Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990â€“2013. <i>Vaccine</i> , 2016, 34, 2841-2846.	1.7	17
38	Deaths Reported to the Vaccine Adverse Event Reporting System, United States, 1997â€“2013. <i>Clinical Infectious Diseases</i> , 2015, 61, 980-987.	2.9	35
39	Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). <i>Vaccine</i> , 2015, 33, 4398-4405.	1.7	416
40	Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax®) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013â€“2015. <i>Vaccine</i> , 2015, 33, 6684-6688.	1.7	19